Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 279

1.

Safety of Iohexol Administration to Measure Glomerular Filtration Rate in Different Patient Populations: A 25-Year Experience.

Gaspari F, Thakar S, Carrara F, Perna A, Trillini M, Aparicio MC, Diadei O, Ferrari S, Cannata A, Stucchi N, Ruggenenti P, Remuzzi G, Perico N.

Nephron. 2018;140(1):1-8. doi: 10.1159/000489898. Epub 2018 May 17.

PMID:
29772565
2.

Blood Pressure and Metabolic Effects of Acetyl-l-Carnitine in Type 2 Diabetes: DIABASI Randomized Controlled Trial.

Parvanova A, Trillini M, Podestà MA, Iliev IP, Aparicio C, Perna A, Peraro F, Rubis N, Gaspari F, Cannata A, Ferrari S, Bossi AC, Trevisan R, Parameswaran S, Chávez-Iñiguez JS, Masnic F, Seck SM, Jiamjariyaporn T, Cortinovis M, Perico L, Sharma K, Remuzzi G, Ruggenenti P, Warnock DG.

J Endocr Soc. 2018 Mar 22;2(5):420-436. doi: 10.1210/js.2017-00426. eCollection 2018 May 1.

3.

Invited letter in response to: "Is the kidney donor profile index (KDPI) universal or UNOS-specific?"

Ruggenenti P, Remuzzi G.

Am J Transplant. 2018 Apr;18(4):1033-1034. doi: 10.1111/ajt.14652. Epub 2018 Feb 3. No abstract available.

PMID:
29316192
4.

Kidney Transplantation in Patients With Atypical Hemolytic Uremic Syndrome: A Therapeutic Dilemma (or Not)?

Noris M, Ruggenenti P, Remuzzi G.

Am J Kidney Dis. 2017 Dec;70(6):754-757. doi: 10.1053/j.ajkd.2017.08.005. No abstract available.

PMID:
29169515
5.

Moderate salt restriction with or without paricalcitol in type 2 diabetes and losartan-resistant macroalbuminuria (PROCEED): a randomised, double-blind, placebo-controlled, crossover trial.

Parvanova A, Trillini M, Podestà MA, Iliev IP, Ruggiero B, Abbate M, Perna A, Peraro F, Diadei O, Rubis N, Gaspari F, Carrara F, Stucchi N, Belviso A, Bossi AC, Trevisan R, Remuzzi G, de Borst M, Ruggenenti P; PROCEED Study Organization and the Scientific Writing Academy (SWA) 2016.

Lancet Diabetes Endocrinol. 2018 Jan;6(1):27-40. doi: 10.1016/S2213-8587(17)30359-5. Epub 2017 Nov 2.

PMID:
29104158
6.

Long-term outcome of renal transplantation from octogenarian donors: A multicenter controlled study.

Ruggenenti P, Silvestre C, Boschiero L, Rota G, Furian L, Perna A, Rossini G, Remuzzi G, Rigotti P.

Am J Transplant. 2017 Dec;17(12):3159-3171. doi: 10.1111/ajt.14459. Epub 2017 Sep 15.

PMID:
28792681
7.

Treatment of membranous nephropathy: time for a paradigm shift.

Ruggenenti P, Fervenza FC, Remuzzi G.

Nat Rev Nephrol. 2017 Sep;13(9):563-579. doi: 10.1038/nrneph.2017.92. Epub 2017 Jul 3. Review.

PMID:
28669992
8.

Dual renin-angiotensin system blockade for nephroprotection.

Ruggenenti P.

Nephrol Ther. 2017 Apr;13 Suppl 1:S43-S45. doi: 10.1016/j.nephro.2017.02.006.

PMID:
28577742
9.

Safety of Rituximab Compared with Steroids and Cyclophosphamide for Idiopathic Membranous Nephropathy.

van den Brand JAJG, Ruggenenti P, Chianca A, Hofstra JM, Perna A, Ruggiero B, Wetzels JFM, Remuzzi G.

J Am Soc Nephrol. 2017 Sep;28(9):2729-2737. doi: 10.1681/ASN.2016091022. Epub 2017 May 9.

10.

ACE and SGLT2 inhibitors: the future for non-diabetic and diabetic proteinuric renal disease.

Perico N, Ruggenenti P, Remuzzi G.

Curr Opin Pharmacol. 2017 Apr;33:34-40. doi: 10.1016/j.coph.2017.03.006. Epub 2017 May 5. Review.

PMID:
28482281
11.

Preventing nephropathy in type 2 diabetes.

Ruggenenti P.

G Ital Nefrol. 2016 Malattie Metaboliche e Rene;33(S68). pii: gin/33.S68.14. No abstract available.

12.

Conversion from Brand-Name Neoral to the Generic Ciqorin in Stable Renal Transplant Recipients.

Cortinovis M, Gotti E, Trillini M, Carrara F, Gaspari F, Ruggenenti P, Remuzzi G, Perico N.

Nephron. 2017;135(3):173-180. doi: 10.1159/000453671. Epub 2016 Dec 10.

PMID:
27941326
13.

Achieving remission of proteinuria in childhood CKD.

Ruggenenti P, Cravedi P, Chianca A, Caruso M, Remuzzi G.

Pediatr Nephrol. 2017 Feb;32(2):321-330. doi: 10.1007/s00467-016-3495-1. Epub 2016 Oct 4.

14.

Iohexol plasma clearance for measuring glomerular filtration rate in clinical practice and research: a review. Part 2: Why to measure glomerular filtration rate with iohexol?

Delanaye P, Melsom T, Ebert N, Bäck SE, Mariat C, Cavalier E, Björk J, Christensson A, Nyman U, Porrini E, Remuzzi G, Ruggenenti P, Schaeffner E, Soveri I, Sterner G, Eriksen BO, Gaspari F.

Clin Kidney J. 2016 Oct;9(5):700-4. doi: 10.1093/ckj/sfw071. Epub 2016 Sep 9.

15.

Iohexol plasma clearance for measuring glomerular filtration rate in clinical practice and research: a review. Part 1: How to measure glomerular filtration rate with iohexol?

Delanaye P, Ebert N, Melsom T, Gaspari F, Mariat C, Cavalier E, Björk J, Christensson A, Nyman U, Porrini E, Remuzzi G, Ruggenenti P, Schaeffner E, Soveri I, Sterner G, Eriksen BO, Bäck SE.

Clin Kidney J. 2016 Oct;9(5):682-99. doi: 10.1093/ckj/sfw070. Epub 2016 Aug 23.

16.

Renal and Systemic Effects of Calorie Restriction in Patients With Type 2 Diabetes With Abdominal Obesity: A Randomized Controlled Trial.

Ruggenenti P, Abbate M, Ruggiero B, Rota S, Trillini M, Aparicio C, Parvanova A, Petrov Iliev I, Pisanu G, Perna A, Russo A, Diadei O, Martinetti D, Cannata A, Carrara F, Ferrari S, Stucchi N, Remuzzi G, Fontana L; C.RE.S.O. Study Group.

Diabetes. 2017 Jan;66(1):75-86. doi: 10.2337/db16-0607. Epub 2016 Sep 15.

17.

Progression, Remission and Regression of Chronic Renal Diseases.

Cortinovis M, Ruggenenti P, Remuzzi G.

Nephron. 2016;134(1):20-4. doi: 10.1159/000445844. Epub 2016 Apr 21. Review.

18.

Terminal Complement Inhibitor Eculizumab in Adult Patients With Atypical Hemolytic Uremic Syndrome: A Single-Arm, Open-Label Trial.

Fakhouri F, Hourmant M, Campistol JM, Cataland SR, Espinosa M, Gaber AO, Menne J, Minetti EE, Provôt F, Rondeau E, Ruggenenti P, Weekers LE, Ogawa M, Bedrosian CL, Legendre CM.

Am J Kidney Dis. 2016 Jul;68(1):84-93. doi: 10.1053/j.ajkd.2015.12.034. Epub 2016 Mar 21.

19.

Effect of Sirolimus on Disease Progression in Patients with Autosomal Dominant Polycystic Kidney Disease and CKD Stages 3b-4.

Ruggenenti P, Gentile G, Perico N, Perna A, Barcella L, Trillini M, Cortinovis M, Ferrer Siles CP, Reyes Loaeza JA, Aparicio MC, Fasolini G, Gaspari F, Martinetti D, Carrara F, Rubis N, Prandini S, Caroli A, Sharma K, Antiga L, Remuzzi A, Remuzzi G; SIRENA 2 Study Group.

Clin J Am Soc Nephrol. 2016 May 6;11(5):785-94. doi: 10.2215/CJN.09900915. Epub 2016 Feb 22.

20.

Long-term Effects of Octreotide on Liver Volume in Patients With Polycystic Kidney and Liver Disease.

Pisani A, Sabbatini M, Imbriaco M, Riccio E, Rubis N, Prinster A, Perna A, Liuzzi R, Spinelli L, Santangelo M, Remuzzi G, Ruggenenti P; ALADIN Study Group.

Clin Gastroenterol Hepatol. 2016 Jul;14(7):1022-1030.e4. doi: 10.1016/j.cgh.2015.12.049. Epub 2016 Feb 1.

PMID:
26844873

Supplemental Content

Loading ...
Support Center